Bachelot, Thomas
Filleron, Thomas
Bieche, Ivan
Arnedos, Monica
Campone, Mario
Dalenc, Florence
Coussy, Florence
Sablin, Marie-Paule
Debled, Marc
Lefeuvre-Plesse, Claudia
Goncalves, Anthony
Reynier, Marie-Ange Mouret
Jacot, William
You, Benoit
Barthelemy, Philippe
Verret, Benjamin
Isambert, Nicolas
Tchiknavorian, Xavier
Levy, Christelle
Thery, Jean-Christophe
L’Haridon, Tifenn
Ferrero, Jean-Marc
Mege, Alice
Del Piano, Francesco
Rouleau, Etienne
Tran-Dien, Alicia
Adam, Julien
Lusque, Amelie
Jimenez, Marta
Jacquet, Alexandra http://orcid.org/0000-0001-6377-2487
Garberis, Ingrid
Andre, Fabrice http://orcid.org/0000-0001-5795-8357
Article History
Received: 29 May 2020
Accepted: 20 November 2020
First Online: 18 January 2021
Competing interests
: F.A. received research funding and served as speaker/advisor (compensated to the hospital) for Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Novartis and Lilly. T.B. received research funding and served as speaker/advisor (compensated to the hospital) for Roche, Novartis, Pfizer, Seattle Genetic, Lilly and AstraZeneca. M.A. received research funding and served as speaker/advisor (compensated to the hospital) for Novartis, AstraZeneca, Seattle Genetics, AbbVie and Pfizer. M.C. received research funding and served as speaker/advisor (compensated to the hospital) for AstraZeneca, Novartis, AbbVie, Sanofi, Lilly, Pfizer, Sandoz, ACCORD, G1 Therapeutic, Pierre Fabre Oncology, Servier and Roche. F.D. received research funding and served as speaker/advisor (compensated to the hospital) for Roche, Novartis, Lilly, Pfizer, Eisai, MSD and AstraZeneca. C.L.-P. received research funding and served as speaker/advisor (compensated to the hospital) for AstraZeneca and Roche. A.G. received research funding and served as speaker/advisor (compensated to the hospital) for AstraZeneca, Pfizer, Novartis, Roche, MSD and Lilly. M.-A.M.R. received research funding and served as speaker/advisor for Pfizer, Novartis, Lilly, Roche, MSD and Myriad. W.J. received research funding and served as speaker/advisor for AstraZeneca, Eisai, Lilly, MSD, Novartis, Pfizer and Roche. B.Y. received research funding and served as speaker/advisor (compensated to the hospital) for AstraZeneca, Roche, Amgen, Novartis, GSK, ECS Progastrin, Pfizer, Merck Serono and Bayer. P.B. served as speaker/advisor for Roche, BMS, IPSEN, Janssen Cilag, Pfizer, Novartis, Astellas and EUSA Pharma. N.I. received research funding and served as speaker/advisor (compensated to the hospital) for Ipsen and Transgene. J.-C.T. received research funding and served as speaker/advisor (compensated to the hospital) for Pfizer and AstraZeneca. J.-M.F. received research funding and served as speaker/advisor for Pfizer and Eisai. J.A. received consultant fees from AstraZeneca, Bayer, BMS, MSD and Roche. The following authors have no disclosures: M.D., A.M., X.T., F.D.P., T.F., I.B., I.G., E.R., A.T.-D., A.L., M.J., A.J., F.C., M.-P.S., B.V., C.L., T.L’H. and F.D.